Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Blood - 23 Oct 2014

Bejar Rafael, Lord Allegra, Stevenson Kristen, Bar-Natan Michal, Pérez-Ladaga Albert, Zaneveld Jacques, Wang Hui, Caughey Bennett, Stojanov Petar, Getz Gad, Garcia-Manero Guillermo, Kantarjian Hagop, Chen Rui, Stone Richard M, Neuberg Donna, Steensma David P, Ebert Benjamin L

Abstract excerpt

Only a minority of myelodysplastic syndrome (MDS) patients respond to hypomethylating agents (HMAs), but strong predictors of response are unknown. We sequenced 40 recurrently mutated myeloid malignancy genes in tumor DNA from 213 MDS patients collected before treatment with azacitidine (AZA) or decitabine (DEC). Mutations were examined for association with response and overall survival. The overall response rate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to Bone Marrow Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decitabine

Share to Dioxygenases

Share to DNA Modification Methylases

Share to Kaplan-Meier Estimate

Share to Myelodysplastic Syndromes

Share to Transplantation Chimera

Source

Open in PubMed Open full text

Identifiers

PMID: 25224413
DOI: 10.1182/blood-2014-06-582809
PMCID: PMC4208285

Genes

TET2
ASXL1
PTPN11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.PMID 25224413Read ↗

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromesSemantic proximity Read ↗

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.Semantic proximity Read ↗

Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?Semantic proximity Read ↗

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.Semantic proximity Read ↗

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.Semantic proximity Read ↗

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDSSemantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Response Predictors and Clonal Evolution during Thalidomide Therapy in Myelodysplastic Neoplasms with Increased BlastsSemantic proximity Read ↗

Mutations and karyotype predict treatment response in myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.